No Yes Ok

Archive

« Older Entries Newer Entries »

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens Tuesday, July 23rd, 2019
Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4% Unyvero provides results after approximately five hours, compared [...]
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC) Monday, July 22nd, 2019
US Food and Drug Administration (FDA) agrees to Orphazyme’s plan to file New Drug Application (NDA) in US On track to file NDA and Marketing Authorisation Application (MAA) in NPC in both US and EU in H1 [...]
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis Thursday, July 18th, 2019
Headline results from full analysis expected in H1 2021   Copenhagen, Denmark, July 18, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for pati [...]
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer Thursday, July 18th, 2019
Paul Frohna brings over 15 years of experience in translational medicine and clinical and regulatory strategy   Marseille, France, 18 July 2019 – ImCheck Therapeutics, a biotech company on the cutting edge [...]
LSP in the FD – ‘Biotechbedrijf AM Pharma haalt €116 mln op’ Tuesday, July 16th, 2019
Today in the Financieele Dagblad 'Biotech company AM Pharma raising €116 mln / Biotechbedrijf AM Pharma haalt €116 mln op ': https://lnkd.in/devNSPM   LSP is leading the €116 mln financing in A [...]
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury Tuesday, July 16th, 2019
Financing led by LSP and co-led by Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to [...]
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer Tuesday, July 16th, 2019
SAN DIEGO, July 16, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammato [...]
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology Tuesday, July 9th, 2019
HALLE (SAALE) and PLANEGG/MUNICH, Germany, 8 July 2019: Vivoryon Therapeutics AG (Euronext Amsterdam: VVY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced that they have [...]
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston Monday, June 24th, 2019
SAN DIEGO, June 24, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammato [...]
LSP's portfolio company Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint ... Wednesday, June 19th, 2019
Article published in Nature Communications   BASEL, Switzerland – 19 June 2019 - Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens Tuesday, July 23rd, 2019
Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4% Unyvero provides results after approximately five hours, compared [...]
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC) Monday, July 22nd, 2019
US Food and Drug Administration (FDA) agrees to Orphazyme’s plan to file New Drug Application (NDA) in US On track to file NDA and Marketing Authorisation Application (MAA) in NPC in both US and EU in H1 [...]
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis Thursday, July 18th, 2019
Headline results from full analysis expected in H1 2021   Copenhagen, Denmark, July 18, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for pati [...]
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer Thursday, July 18th, 2019
Paul Frohna brings over 15 years of experience in translational medicine and clinical and regulatory strategy   Marseille, France, 18 July 2019 – ImCheck Therapeutics, a biotech company on the cutting edge [...]
LSP in the FD – ‘Biotechbedrijf AM Pharma haalt €116 mln op’ Tuesday, July 16th, 2019
Today in the Financieele Dagblad 'Biotech company AM Pharma raising €116 mln / Biotechbedrijf AM Pharma haalt €116 mln op ': https://lnkd.in/devNSPM   LSP is leading the €116 mln financing in A [...]
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury Tuesday, July 16th, 2019
Financing led by LSP and co-led by Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to [...]
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer Tuesday, July 16th, 2019
SAN DIEGO, July 16, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammato [...]
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology Tuesday, July 9th, 2019
HALLE (SAALE) and PLANEGG/MUNICH, Germany, 8 July 2019: Vivoryon Therapeutics AG (Euronext Amsterdam: VVY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced that they have [...]
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston Monday, June 24th, 2019
SAN DIEGO, June 24, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammato [...]
LSP's portfolio company Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoin... Wednesday, June 19th, 2019
Article published in Nature Communications   BASEL, Switzerland – 19 June 2019 - Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund